Category Archives: pricing

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in Biotech, FDA, Guest Blog, healthcare, Legal, Market Access, Marketing, Regulatory, Strategy | Tagged , , | 1 Comment

Sanofi Responds to UK’s Value-Based Assessment Plans

By Leela Barham. The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.  VBA is what value-based pricing (VBP) has essentially morphed into. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 […]
Also posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

Turkey to See Renewed Multinational Investment, Says Report

Turkey is remains a key destination for foreign investment, and the next five years should see renewed interest from pharma multinationals, says a new report by CPhI Worldwide. Although the Turkish government’s price referencing system and fixed euro-lira conversion rate have presented a major obstacle for pharma growth, the report states that these pricing challenges […]
Also posted in Emerging Markets, Europe, Global, Manufacturing, R&D | Tagged , , | Leave a comment

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Also posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, Regulatory | Tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta